应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TBPH Theravance Biopharma Inc.
休市中 10-02 16:00:00 EDT
17.03
+0.00
0.00%
最高
17.03
最低
17.03
成交量
0.00
今开
17.03
昨收
17.03
日振幅
0.00%
总市值
8.83亿
流通市值
4.40亿
总股本
5,183万
成交额
0.00
换手率
0.00%
流通股本
2,586万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费
美股速递 · 06-29
Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费
Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购
美股速递 · 06-29
Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购
Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权
美股速递 · 06-29
Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权
Theravance Biopharma预计重组行动将产生500万至700万美元一次性现金遣散成本
美股速递 · 05-07
Theravance Biopharma预计重组行动将产生500万至700万美元一次性现金遣散成本
Theravance Biopharma Inc宣布重大重组:将终止研发职能并大幅缩减行政开支
美股速递 · 05-07
Theravance Biopharma Inc宣布重大重组:将终止研发职能并大幅缩减行政开支
Theravance Biopharma预计Q3将实现约7000万美元全速运转成本节约
美股速递 · 05-07
Theravance Biopharma预计Q3将实现约7000万美元全速运转成本节约
Theravance Biopharma启动组织架构重组 旨在优化成本与资源配置
美股速递 · 05-07
Theravance Biopharma启动组织架构重组 旨在优化成本与资源配置
Theravance Biopharma成立战略评估委员会 积极寻求股东价值最大化方案
美股速递 · 05-07
Theravance Biopharma成立战略评估委员会 积极寻求股东价值最大化方案
Theravance Biopharma, Inc.盘中异动 大幅拉升5.16%报9.57美元
市场透视 · 2025-03-06
Theravance Biopharma, Inc.盘中异动 大幅拉升5.16%报9.57美元
Theravance Biopharma, Inc.2024财年实现净利润-56.42百万美元,同比减少2.23%
市场透视 · 2025-03-03
Theravance Biopharma, Inc.2024财年实现净利润-56.42百万美元,同比减少2.23%
Theravance Biopharma, Inc.盘中异动 股价大涨8.81%
市场透视 · 2025-02-27
Theravance Biopharma, Inc.盘中异动 股价大涨8.81%
Theravance Biopharma 第四季度调整后EPS $(0.05) 优于预期 $(0.21),销售额 $1875万 超预期 $1709万
财报速递 · 2025-02-27
Theravance Biopharma 第四季度调整后EPS $(0.05) 优于预期 $(0.21),销售额 $1875万 超预期 $1709万
Theravance Biopharma, Inc.盘中异动 临近收盘急速跳水5.05%
市场透视 · 2025-02-25
Theravance Biopharma, Inc.盘中异动 临近收盘急速跳水5.05%
Theravance Biopharma, Inc.盘中异动 急速下跌5.16%
市场透视 · 2025-01-27
Theravance Biopharma, Inc.盘中异动 急速下跌5.16%
Theravance Biopharma, Inc.盘中异动 早盘股价大涨6.51%报10.30美元
市场透视 · 2025-01-25
Theravance Biopharma, Inc.盘中异动 早盘股价大涨6.51%报10.30美元
Theravance Biopharma, Inc.盘中异动 急速拉升5.01%报9.01美元
市场透视 · 2025-01-22
Theravance Biopharma, Inc.盘中异动 急速拉升5.01%报9.01美元
Theravance Biopharma, Inc.盘中异动 股价大涨5.06%报9.97美元
市场透视 · 2024-11-20
Theravance Biopharma, Inc.盘中异动 股价大涨5.06%报9.97美元
Theravance Biopharma, Inc.盘中异动 早盘快速上涨6.29%报9.47美元
市场透视 · 2024-11-13
Theravance Biopharma, Inc.盘中异动 早盘快速上涨6.29%报9.47美元
Theravance Biopharma, Inc.盘中异动 股价大涨5.14%报8.70美元
市场透视 · 2024-11-07
Theravance Biopharma, Inc.盘中异动 股价大涨5.14%报8.70美元
Theravance Biopharma, Inc.盘中异动 大幅拉升6.01%
市场透视 · 2024-10-16
Theravance Biopharma, Inc.盘中异动 大幅拉升6.01%
暂无数据
公司概况
公司名称:
Theravance Biopharma Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Theravance Biopharma, Inc.于2013年7月注册为开曼群岛豁免股份有限公司。该公司是一家生物制药公司,主要专注于药物的发现、开发和商业化。该公司的核心宗旨是创造能够改变人们生活的药物。该公司利用数十年的专业知识,开发了FDA批准的YUPELRI(revefenacin)吸入溶液,用于慢性阻塞性肺病患者的维持治疗。
发行价格:
--
{"stockData":{"symbol":"TBPH","market":"US","secType":"STK","nameCN":"Theravance Biopharma Inc.","latestPrice":17.03,"timestamp":1790971200000,"preClose":17.03,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":25856900,"shares":51828254,"eps":1.045057,"marketStatus":"休市中","change":0,"latestTime":"10-02 16:00:00 EDT","open":17.03,"high":17.03,"low":17.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.045057,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1400212800000,"exchange":"NASDAQ","adjPreClose":17.03,"volumeRatio":0,"impliedVol":0.2331,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/TBPH/tweets","defaultTab":"tweets","newsList":[{"id":"1146396391","title":"Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1146396391","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146396391?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:38","pubTimestamp":1782729520,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 披露,根据其与Zymeworks Inc.达成的协议条款,若交易在特定情况下被终止,公司将需向Zymeworks支付一笔高达3250万美元的终止费用。\n此项财务安排明确了交易未能完成时的责任归属,为双方的合作设定了清晰的退出机制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139","BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136977316","title":"Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1136977316","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136977316?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:04","pubTimestamp":1782727469,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma Inc.的股价在盘前交易时段遭遇显著下滑,跌幅达到3.3%。此前,该公司宣布已与Zymeworks Inc.达成收购协议。根据协议条款,Zymeworks将以每股17美元的现金价格收购Theravance Biopharma的全部流通股,此外,交易还包含一项或有价值权安排。此项收购案为Theravance Biopharma的股东提供了直接的现金对价,并结合了基于未来特定里程碑达成情况而可能支付的额外价值。交易细节的公布通常会引起股价波动,此次盘前下跌正是市场对收购条款进行初步定价与权衡的直接体现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4007","BK4139","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194792603","title":"Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权","url":"https://stock-news.laohu8.com/highlight/detail?id=1194792603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194792603?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:02","pubTimestamp":1782727338,"startTime":"0","endTime":"0","summary":"Theravance Biopharma公司宣布,其股东将有权获得一项或有价值权(CVR),该权利与Ampreloxetine资产变现所产生的净收益挂钩。具体而言,股东将有权分享该资产净收益的80%。这一安排旨在将未来潜在的价值创造直接回馈给公司股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ZYME","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118910752","title":"Theravance Biopharma预计重组行动将产生500万至700万美元一次性现金遣散成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1118910752","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118910752?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:44","pubTimestamp":1778157864,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma宣布,因实施重组计划,预计将承担约500万至700万美元的一次性现金遣散费用。此次重组行动旨在优化公司运营结构,相关成本主要涉及员工离职补偿。该笔费用将作为特殊项目计入财务报表,不影响公司核心业务的持续经营能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173514028","title":"Theravance Biopharma Inc宣布重大重组:将终止研发职能并大幅缩减行政开支","url":"https://stock-news.laohu8.com/highlight/detail?id=1173514028","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173514028?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:39","pubTimestamp":1778157573,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc近日公布了一项重大战略调整方案,公司决定全面终止研发部门运作,并对行政管理部门进行大规模精简。这一重组举措标志着该生物制药企业将彻底转变其运营模式与发展方向。根据公告内容,此次重组涉及两个核心层面:研发职能的逐步退出与行政管理职能的实质性压缩。这项重大调整预计将对公司未来业务布局产生深远影响。随着研发职能的退出,Theravance Biopharma将重新聚焦于现有产品的商业化运营与市场拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164724538","title":"Theravance Biopharma预计Q3将实现约7000万美元全速运转成本节约","url":"https://stock-news.laohu8.com/highlight/detail?id=1164724538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164724538?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:39","pubTimestamp":1778157555,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma宣布,其约7000万美元的全速运转成本节约计划预计将在第三季度全面落地。这一重要财务目标若能如期达成,将显著优化公司运营效率,为后续研发投入释放更多资金空间。\n成本控制举措的完整效益显现,标志着企业战略执行进入关键阶段。在当前生物科技行业融资环境趋紧的背景下,实现预期节流目标对维持现金流健康与研发持续性具有战略意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195682611","title":"Theravance Biopharma启动组织架构重组 旨在优化成本与资源配置","url":"https://stock-news.laohu8.com/highlight/detail?id=1195682611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195682611?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:35","pubTimestamp":1778157335,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 宣布正式实施一项组织架构重组计划。该举措旨在系统性地精简运营成本,并使公司资源更高效地与其战略重点保持一致。此次重组预计将优化公司的财务结构,提升整体运营效率。\n通过这次调整,公司期望能够更灵活地应对市场变化,集中资源推进核心研发项目,为未来的长期增长奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118664421","title":"Theravance Biopharma成立战略评估委员会 积极寻求股东价值最大化方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1118664421","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118664421?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:31","pubTimestamp":1778157118,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc.(简称:Theravance Biopharma)已正式组建战略评估委员会,该委员会正全面评估各类战略机遇,旨在最大化股东价值。这一举措表明公司管理层正积极应对市场变化,致力于通过系统性评估为公司未来发展确定最优路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517427629","title":"Theravance Biopharma, Inc.盘中异动 大幅拉升5.16%报9.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517427629","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517427629?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:20","pubTimestamp":1741195237,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时20分,Theravance Biopharma, Inc.股票出现波动,股价急速拉升5.16%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体涨幅为1.15%。其相关个股中,Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为933.95%、303.15%、289.83%,振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.,振幅分别为82.59%、54.27%、47.22%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012037989d6bab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012037989d6bab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516754802","title":"Theravance Biopharma, Inc.2024财年实现净利润-56.42百万美元,同比减少2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516754802","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516754802?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931279,"startTime":"0","endTime":"0","summary":"3月3日,Theravance Biopharma, Inc.公布财报,公告显示公司2024财年净利润为-56.42百万美元,同比减少2.23%;其中营业收入为64.38百万美元,同比增加12.12%,每股基本收益为-1.16美元。机构评级:截至2025年3月3日,当前有4家机构对Theravance Biopharma, Inc.目标价做出预测,其中目标均价为14.50美元,其中最低目标价为10.00美元,最高目标价为21.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000156a25bbc84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000156a25bbc84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385130","title":"Theravance Biopharma, Inc.盘中异动 股价大涨8.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385130?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666678,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分,Theravance Biopharma, Inc.股票出现异动,股价急速上涨8.81%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Quoin Pharmaceuticals Ltd、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大,Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为394.03%、90.29%、48.43%,振幅较大的相关个股有天演药业、Syros Pharmaceuticals, Inc.、内克塔治疗,振幅分别为10.10%、10.09%、7.64%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223118abdf6e6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223118abdf6e6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107161536","title":"Theravance Biopharma 第四季度调整后EPS $(0.05) 优于预期 $(0.21),销售额 $1875万 超预期 $1709万","url":"https://stock-news.laohu8.com/highlight/detail?id=1107161536","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107161536?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:33","pubTimestamp":1740605625,"startTime":"0","endTime":"0","summary":"Theravance Biopharma 公布季度每股亏损 $,比分析师一致预期的 $ 高出76.19%。这比去年同期每股亏损 $ 增加了70.59%。以上内容来自Benzinga Earnings专栏,原文如下:Theravance Biopharma reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 76.19 percent. This is a 70.59 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $18.75 million which beat the analyst consensus estimate of $17.09 million by 9.73 percent. This is a 6.77 percent increase over s","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Theravance Biopharma 第四季度调整后EPS $(0.05) 优于预期 $(0.21),销售额 $1875万 超预期 $1709万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514705216","title":"Theravance Biopharma, Inc.盘中异动 临近收盘急速跳水5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514705216?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:55","pubTimestamp":1740430544,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时55分,Theravance Biopharma, Inc.股票出现波动,股价大幅下挫5.05%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体跌幅为0.41%。其相关个股中,Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大,Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为332.71%、145.46%、41.78%,振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ,振幅分别为176.22%、164.23%、81.92%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022504554498913f99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022504554498913f99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506309225","title":"Theravance Biopharma, Inc.盘中异动 急速下跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506309225","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506309225?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:14","pubTimestamp":1737990865,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时14分,Theravance Biopharma, Inc.股票出现波动,股价快速下跌5.16%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体涨幅为0.98%。其相关个股中,Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大,Onconetix, Inc.、Evaxion Biotech As、Dogwood Therapeutics, Inc.较为活跃,换手率分别为1714.17%、188.57%、164.70%,振幅较大的相关个股有阿诺医药、Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为98.54%、85.35%、65.16%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012723142696124086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012723142696124086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506908860","title":"Theravance Biopharma, Inc.盘中异动 早盘股价大涨6.51%报10.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506908860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506908860?lang=zh_cn&edition=full","pubTime":"2025-01-25 00:19","pubTimestamp":1737735568,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日00时19分,Theravance Biopharma, Inc.股票出现波动,股价快速拉升6.51%。截至发稿,该股报10.30美元/股,成交量8.9241万股,换手率0.18%,振幅5.44%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体跌幅为0.05%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125001929a22e7240&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125001929a22e7240&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505205340","title":"Theravance Biopharma, Inc.盘中异动 急速拉升5.01%报9.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505205340","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505205340?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:16","pubTimestamp":1737476195,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日00时16分,Theravance Biopharma, Inc.股票出现异动,股价快速拉升5.01%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体涨幅为1.63%。其相关个股中,Channel Therapeutics Corporation、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Dogwood Therapeutics, Inc.涨幅较大,Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃,换手率分别为755.88%、472.32%、182.27%,振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.,振幅分别为96.32%、41.33%、38.48%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122001635986e4695&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122001635986e4695&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484979041","title":"Theravance Biopharma, Inc.盘中异动 股价大涨5.06%报9.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484979041","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484979041?lang=zh_cn&edition=full","pubTime":"2024-11-20 02:41","pubTimestamp":1732041679,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日02时41分,Theravance Biopharma, Inc.股票出现波动,股价快速上涨5.06%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体跌幅为1.33%。其相关个股中,Syros Pharmaceuticals, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Syros Pharmaceuticals, Inc.、Tff Pharmaceuticals, Inc.、Exicure, Inc.较为活跃,换手率分别为1019.69%、836.68%、141.70%,振幅较大的相关个股有Syros Pharmaceuticals, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ,振幅分别为91.10%、81.67%、62.82%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112002411998e4391e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112002411998e4391e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483300884","title":"Theravance Biopharma, Inc.盘中异动 早盘快速上涨6.29%报9.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483300884","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483300884?lang=zh_cn&edition=full","pubTime":"2024-11-13 22:31","pubTimestamp":1731508275,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日22时31分,Theravance Biopharma, Inc.股票出现异动,股价快速拉升6.29%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体涨幅为0.05%。其相关个股中,Celularity Inc C/Wts 16/07/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Kairos Pharma, Ltd.涨幅较大,Cyclacel Pharmaceuticals, Inc.、Elevai Labs, Inc.、Tharimmune, Inc.较为活跃,换手率分别为323.85%、168.31%、84.06%,振幅较大的相关个股有Entero Therapeutics Inc.、Turnstone Biologics Corp.、Cyclacel Pharmaceuticals, Inc.,振幅分别为8.29%、7.65%、7.63%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111322311595be230e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111322311595be230e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481939798","title":"Theravance Biopharma, Inc.盘中异动 股价大涨5.14%报8.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481939798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481939798?lang=zh_cn&edition=full","pubTime":"2024-11-07 02:02","pubTimestamp":1730916162,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日02时02分,Theravance Biopharma, Inc.股票出现波动,股价急速上涨5.14%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体跌幅为0.35%。其相关个股中,60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 、Sonnet Biotherapeutics Holdings, Inc.涨幅较大,Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃,换手率分别为3021.40%、425.92%、133.19%,振幅较大的相关个股有Cardio Diagnostics Holdings Inc.、Sonnet Biotherapeutics Holdings, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ,振幅分别为82.72%、77.67%、57.62%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107020242a21d9460&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107020242a21d9460&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2475667712","title":"Theravance Biopharma, Inc.盘中异动 大幅拉升6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475667712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2475667712?lang=zh_cn&edition=full","pubTime":"2024-10-16 03:48","pubTimestamp":1729021733,"startTime":"0","endTime":"0","summary":"北京时间2024年10月16日03时48分,Theravance Biopharma, Inc.股票出现波动,股价快速上涨6.01%。Theravance Biopharma, Inc.股票所在的生物技术行业中,整体跌幅为0.57%。其相关个股中,Bright Minds Biosciences Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大,Bright Minds Biosciences Inc.、Salarius Pharmaceuticals, Inc.、Aditxt, Inc.较为活跃,换手率分别为2154.74%、501.88%、413.94%,振幅较大的相关个股有Bright Minds Biosciences Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Apollomics Inc C/Wts 01/04/2028 ,振幅分别为1204.82%、173.40%、123.44%。Theravance Biopharma, Inc.公司简介:Theravance Biopharma Inc 是一家多元化的生物制药公司,专注于器官选择性药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101603485398e3c9dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101603485398e3c9dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.theravance.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0023},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.063},{"period":"1year","weight":0.2104},{"period":"ytd","weight":-0.0898}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Theravance Biopharma, Inc.于2013年7月注册为开曼群岛豁免股份有限公司。该公司是一家生物制药公司,主要专注于药物的发现、开发和商业化。该公司的核心宗旨是创造能够改变人们生活的药物。该公司利用数十年的专业知识,开发了FDA批准的YUPELRI(revefenacin)吸入溶液,用于慢性阻塞性肺病患者的维持治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.019808},{"month":2,"riseRate":0.25,"avgChangeRate":0.006017},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.001894},{"month":4,"riseRate":0.583333,"avgChangeRate":0.039067},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.067072},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.016553},{"month":7,"riseRate":0.384615,"avgChangeRate":0.003583},{"month":8,"riseRate":0.692308,"avgChangeRate":0.018831},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.028001},{"month":10,"riseRate":0.461538,"avgChangeRate":-0.023577},{"month":11,"riseRate":0.75,"avgChangeRate":0.113018},{"month":12,"riseRate":0.583333,"avgChangeRate":0.041602}],"exchange":"NASDAQ","name":"Theravance Biopharma Inc.","nameEN":"Theravance Biopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Theravance Biopharma Inc.(TBPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Theravance Biopharma Inc.(TBPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Theravance Biopharma Inc.,TBPH,Theravance Biopharma Inc.股票,Theravance Biopharma Inc.股票老虎,Theravance Biopharma Inc.股票老虎国际,Theravance Biopharma Inc.行情,Theravance Biopharma Inc.股票行情,Theravance Biopharma Inc.股价,Theravance Biopharma Inc.股市,Theravance Biopharma Inc.股票价格,Theravance Biopharma Inc.股票交易,Theravance Biopharma Inc.股票购买,Theravance Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Theravance Biopharma Inc.(TBPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Theravance Biopharma Inc.(TBPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}